Recent Posts in ‘Biotech News’
Cardium (CXM) Reports New Gene Delivery Methods at Industry Conference
Cardium Therapeutics (NYSE Amex: CXM), a health sciences and regenerative company focused on the acquisition of new and innovative bio-medical product opportunities and businesses with the potential to address significant unmet medical needs and definable pathways to commercialization, like companies such as Impax Laboratories Inc. (Nasdaq: IPXL) and Biogen Idec Inc. (Nasdaq: BIIB), reported that
Cardium (CXM) Announces Excellagen Supply Agreement and Planned Expansion
Cardium Therapeutics (NYSE MKT: CXM), a health sciences and regenerative medicine company focused on the acquisition of new and innovative bio-medical product opportunities and businesses with the potential to address significant unmet medical needs and definable pathways to commercialization, with a wound care product targeting the same industry as companies like 3M Company (NYSE: MMM)
BioLargo (BLGO) Enters into Wound Care Industry
BioLargo Inc. (OTCBB: BLGO), creator of patented iodine technologies, recently announced its entry into the wound care industry with the formation of a wholly owned subsidiary, BioLargo Medical Group, Inc. In today’s press release the company also announced the development of novel antimicrobial products for the wound care industry. The move could result in a
Cellceutix IND Filing Imminent after Capital Raise
Cellceutix Corporation (OTC.BB: CTIX) (the “Company”), a biopharmaceutical company developing a novel drug to treat cancers and cancers which have proven resistant to today’s cancer therapies (drug-resistant cancers), is pleased to report that it has successfully negotiated terms and entered into a subscription agreement for Series A Convertible Preferred shares with an accredited investor for an aggregate
Syracuse Basketball Icon Jim Boeheim Joins Cellceutix to Fight Cancer
Cellceutix Corporation (CTIX) (the “Company”), a biopharmaceutical company developing a novel drug to treat cancers and cancers which have proven resistant to today’s cancer therapies (drug-resistant cancers), is pleased to announce that Syracuse University’s legendary men’s basketball coach Jim Boeheim has joined Cellceutix as an advisor to the Company. Coach Boeheim has earned icon status in the
Pressure BioSciences (PBIO) Announces Strategic Partnership with LEAP Technologies
Pressure BioSciences Inc. (OTCQB: PBIO), a developer of proprietary laboratory instrumentation and associated consumables based on Pressure Cycling Technology (“PCT”), operating in the same industry as companies like Qiagen NV (NASDAQ: QGEN) and Becton, Dickenson and Co. (NYSE: BDX), recently announced a strategic co-development, co-marketing and co-selling agreement with well known LEAP Technologies, which is focused
Cellceutix CEO Leo Ehrlich Interviewed by TheStreetBeat.com
TheStreetBeat.com is pleased to announce the latest installment of its CEO Interview Series. A two-part interview will begin airing today featuring a question and answer session with Cellceutix Corporation(CTIX.OB) Chief Executive Officer Leo Ehrlich. Cellceutix, a biopharmaceutical company developing small molecule drugs to treat severe medical conditions, including drug-resistant cancers, is rapidly emerging in the biotech space and
ALR Technologies (ALRT) Taglich Brothers Analyst Report in PowerPoint
ALR Technologies Inc. (OTCBB: ALRT), developer of the FDA-cleared Health-e-Connect (HeC) system to monitor patient compliance, operating in the same industry as other companies in the diabetes testing space like Abbott Laboratories (NYSE: ABT) and Bayer AG (PINK: BAYRY), was recently the focus of a Taglich Brothers analyst report. To view the complete report, please
Pressure BioSciences (PBIO) Deal Lauded by Zacks Research
Pressure BioSciences, Inc. (OTCQB: PBIO), a developer of proprietary lab instrumentation and associated consumables based on its game changing Pressure Cycling Technology (PCT), providing equipment to companies like Thermo Fisher Scientific (NYSE: TMO) and Amgen Inc. (NASDAQ: AMGN), was recently praised by Zacks Research for its favorable financing. According to Zack’s report on the topic, the key takeaway
Cardium’s (CXM) MedPodium Nutra-Apps® Expands Distribution
Cardium Therapeutics (NYSE Amex: CXM), a health sciences and regenerative medicine company focused on the acquisition of new and innovative bio-medical product opportunities and businesses with the potential to address significant unmet medical needs and definable pathways to commercialization, offering product lines similar to companies such as Nutraceutical International Corp (NASDAQ: NUTR) and Schiff Nutrition
Stem Cell Headlines Highlight Importance of FDA Decisions to Athersys (ATHX) and Others
Companies mentioned in this article include Neuralstem Inc. (AMEX: CUR), StemCells Inc. (NASDAQ: STEM), and Athersys Inc. (NASDAQ: ATHX). There’s no arguing that stem cells therapies have been a hot button topic of controversy for years. The days are few and far between where there isn’t something in the media that highlights some aspect of
Pressure BioSciences (PBIO) Secures $500K Investment on Very Attractive Terms
Pressure BioSciences Inc. (OTCQB: PBIO), a developer of proprietary laboratory instrumentation and associated consumables based on its game-changing Pressure Cycling Technology (PCT), competing against other companies in the sample preparation technology sector, like Qiagen NV (NASDAQ: QGEN) and Becton, Dickenson and Co. (NYSE: BDX), just announced that they had secured a $500,000 preferred stock investment